Matthew H. Kulke

Matthew H. Kulke, MD, MMSc is Chief of Hematology and Oncology at Boston Medical Center and Professor of Medicine at Boston University School of Medicine. Previously a longtime faculty member and program director at Dana-Farber Cancer Institute and Harvard Medical School, he is one of the most influential clinical investigators in the field of neuroendocrine tumors globally, with over two decades of leadership in designing and executing pivotal phase II and phase III trials that have defined current standards of care for advanced NETs. His research encompasses pancreatic NETs, midgut carcinoids, and functional NETs with refractory carcinoid syndrome. Dr. Kulke was a principal investigator for the RADIANT series of trials evaluating everolimus in advanced NETs, including the landmark RADIANT-3 trial that led to FDA approval of everolimus for pancreatic NETs in 2011, and the RADIANT-4 trial demonstrating benefit in non-functional lung and gastrointestinal NETs. He also led the TELECAST trial that established telotristat ethyl as the first new agent for carcinoid syndrome diarrhea in decades. His translational work has characterized molecular mechanisms driving NET progression and resistance to targeted therapy. A past president of the North American Neuroendocrine Tumor Society (NANETS), Dr. Kulke has authored over 250 peer-reviewed publications and co-authored NCCN and ESMO clinical practice guidelines for NETs. He is a frequent invited speaker at ASCO, ESMO, and ENETS annual meetings.